Bullous pemphigoid (BP) is the most common autoimmunemediated subepidermal blistering skin disease and occurs mostly in elderly persons. The association of malignant neoplasms with BP has been controversial. 1 This study compared the incidence of cancer in patients with BP with that of the ageand sex-matched general population. with BP were matched with persons in the Singapore Cancer Registry and Death Registry to identify those who had cancer and/or had died. Person-years were accrued from BP diagnosis until death, cancer diagnosis, or December 31, 2011, whichever was earliest. The expected number of cancer cases was calculated as the exposure multiplied by the incidence within each age-and sex-specific category and then summed across all categories for the period 2004-2008 in Singapore. The standardized incidence ratio was calculated as the ratio of observed to expected cancers, and 95% CIs were calculated for the standard incidence ratio based on Poisson distribution. The study was approved by the ethics committee of the National Healthcare Group, Singapore. Patient consent was waived.
Results | A total of 359 patients with BP (mean age, 75.7 years; range, 27.8-100.8 years) were included ( Table 1) . Of these, 48 (13.4%) had a malignant neoplasm, of which 16 preceded BP diagnosis by more than 5 years (mean, 17.1 years; range, 6.8-26.9 years). Of the 32 recent cancers, 14 occurred within 5 years preceding BP diagnosis. The remaining 18 occurred either in the same year as a BP diagnosis (n = 4) or after BP diagnosis (n = 14). These included 6 lung cancers, 5 skin cancers (nonmelanoma), 3 colorectal cancers, 2 breast cancers, 1 pancreatic cancer, and 1 prostate cancer. The mean follow-up period from BP diagnosis was 2.5 years (range, 0.2-7.4 years); the mean time from BP diagnosis to cancer diagnosis was 0.9 years (range, -1.0 to -4.2 years). The mean time from cancer diagnosis to death was 1.3 years (range, 0-7.4 years), and 7 of the 15 deaths (46.7%) that occurred during follow-up were cancer related.
The expected number of incident cancer diagnoses after BP diagnosis was 14.48, with 14 cancers observed (within 4.2 years) after BP diagnosis, yielding an age-and sex-matched standard incidence ratio of 0.97 (95% CI, 0.53-1.62) ( Table 2) . There was no association with malignant neoplasms, even when cancers in the concurrent year but preceding BP diagnosis or up to 5 years preceding BP diagnosis were included. No association was observed with any particular type of malignant neoplasm. While studies initially reported an association between BP and cancer, 1 subsequent studies 4, 5 have refuted this association, including a recent British study. 6 Although there is a possibility of increased risk of malignant neoplasm in younger patients with BP, 7 we did not find this association.
Discussion | Our study found no significant increase in the incidence of cancer among patients with BP compared with those in the age-and sex-matched general population. Strengths of this study included a relatively large, welldefined cohort, comprehensive patient capture at a national dermatology referral center, complete verification of cancer incidence and mortality status with the national cancer registry, and long-term follow-up. Bias toward greater surveillance for cancer was unlikely because there was no institutional practice to screen patients with BP for malignant neoplasms.
Our data support the findings that BP is not associated with an increased incidence of malignant neoplasms. Thus, cancer screening may not be indicated based on a diagnosis of BP per se, but it should be individualized according to the age, history, and physical evaluation of the patient. The use of silver for medicinal purposes dates back to the eighth century CE and is still in use today. 1-3 Generalized argyria is characterized by slate-gray to blue discoloration of the skin caused by cutaneous deposits of silver particles after long-term ingestion of solutions containing colloidal silver ingredients or silver salts. 1-3 The skin discoloration is more prominent in sun-exposed areas and is usually permanent. There is no widely accepted effective treatment for the skin discoloration of argyria. 4(p44653) Despite the FDA's warning, colloidal silver remains accessible from at least 2 major online retailers and is being marketed as a dietary supplement that will improve health. The product description of one ingestible liquid product containing colloidal silver from Walmart.com claims it can "eliminate toxins, poisons and fungi from your body" and that it will "keep your system's defenses against toxins and viruses high" (both quotations from http://url.ie/ylm7).
Methods | To investigate the current availability of colloidal silver solution in one major online marketplace, the term colloidal silver was searched on Amazon.com on June 13, 2014. The search yielded 2286 different colloidal silver products. The products were then limited to only those listed in the health and personal care department, which yielded 1010 different products. The results were then limited to only liquid colloidal silver products, which yielded 149 different products; only these ingestible liquid colloidal silver products were analyzed. The search results were sorted by relevance, not by rating.
Results | Twenty-four different ingestible liquid products containing colloidal silver were listed on the first page of the search results; only products on this first page of the results that had at least 10 consumer reviews were included for analysis. These criteria yielded 12 colloidal silver products with a combined total of 606 individual customer reviews (mean, 50.5 reviewers per product). The mean consumer rating of these 12 products was 4.38 of a possible maximum rating of 5 stars.
Discussion | The availability of colloidal silver solution as a health and personal care product is concerning. With the use of an online marketplace, colloidal silver can be easily obtained, and consumers can be influenced by the favorable product reviews. It is important that a patient's medical history include information about over-the-counter medications, dietary supplements, and complementary and alternative medications. The most common adverse effect of long-term colloidal silver ingestion is argyria. Advising patients against further use can prevent worsening of skin discoloration and development of renal, hepatic, and neurologic problems that have been reported after long-term ingestion of colloidal silver. 4 In addition, the FDA warning made 16 years ago should be reemphasized and consideration should be given to adding colloidal silver to the list of the agency's Unapproved Drugs Initiative since it poses a potential safety risk and lacks evidence of being effective.
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